CPhI Worldwide is the world's leading pharmaceutical networking event for Pharma Ingredients. Along with co-located events ICSE for Contract Services, InnoPack for Innovative Packaging and P-MEC Europe for Technology, Equipment and Machinery, this is a one-stop shop event that cannot be missed by anyone serving the (Bio)Pharmaceutical industry.
CPhI Worldwide is the world's leading pharmaceutical networking event for Pharma Ingredients. Along with co-located events ICSE for Contract Services, InnoPack for Innovative Packaging and P-MEC Europe for Technology, Equipment and Machinery, this is a one-stop shop event that cannot be missed by anyone serving the (Bio)Pharmaceutical industry.
First launched in 1990, the events have grown to a scope of 2,200 exhibitors and 30,000+ attendees fromover 140 countries. An ideal networking platform, CPhI and co-located events allow you to meet all your business partners under one roof!
CPhI and co-located events host zones for each area of Pharma. From APIs to Generics, from Fine Chemicals to Intermediates and Finished Dosage, Custom Manufacturing and Clinical Trials to Transportation, Lab Devices, Track and Trace and much more.
Where else in the world can you find this many Pharma companies, showcasing their innovations, looking to meet people just like you?
Drop by from 9-11 October 2012 in Feria de Madrid, Spain. Admission is Free of Charge when you register online, unless you purchase a special package.
Register your interest now . We look forward to seeing you there!
Date: October 9, 2012 - October 11, 2012
Contact Info
Website: www.cphi.com
E-mail: cphi@ubm.com
GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease
May 14th 2025Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.